Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

ClinicalTrials.gov ID: NCT02454972

Public ClinicalTrials.gov record NCT02454972. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors

Study identification

NCT ID
NCT02454972
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
PharmaMar
Industry
Enrollment
345 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 24, 2015
Primary completion
Sep 17, 2020
Completion
Sep 17, 2020
Last update posted
Mar 1, 2023

2015 – 2020

United States locations

U.S. sites
7
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
Sarcoma Oncology Research Center, LLC Santa Monica California 90403
University of Colorado Cancer Center Aurora Colorado 80045
Massachussets General Hospital Boston Massachusetts 02114
Beth Israel Deaconess Medical Centre Boston Massachusetts 02215
Dana Farber Cancer Institute Boston Massachusetts 02215
The University of Texas MD Anderson Cancer Center Houston Texas 77030
Institute for Drug Development, Cancer Therapy & Research Center at University of Texas Health Science Center San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02454972, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 1, 2023 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02454972 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →